The major obstacles for the efficacy of
tumor immunotherapies are their immune-related systemic adverse events. Therefore,
tumor tropism property and pro-inflammatory ability of mesenchymal stem cells (MSCs) could be utilized in combination to potentiate local immunity for
cancer eradication. We previously observed that MSCs with the type III
histone deacetylase silent information regulator 2 homologue 1 (
Sirt1) overexpression displayed a pro-inflammatory capacity. However, the anti-
tumor effect of Sirt1-overexpressing MSCs and the role of
Sirt1 in regulating the pro-inflammatory capacity of MSCs still need to be clarified. In this study, utilizing the hepatic
metastasis model of
colorectal carcinoma, we demonstrated that Sirt1-overexpressing MSCs significantly exerted anti-
tumor activity through increasing the number of CD8+ T cells. Furthermore,
Sirt1 did not affect
chemokine secretion in MSCs induced by inflammatory
cytokines, but impaired the immunosuppressive ability of MSCs through suppressing inflammatory
cytokine-stimulated
inducible nitric oxide synthase (iNOS) production via deacetylating p65. iNOS overexpression negated the anti-
tumor effect of Sirt1-overexpressing MSCs. Collectively, our data defined
Sirt1 as the critical regulator for modulating the pro-inflammatory ability of MSCs, and they suggested that Sirt1-overexpressing MSCs secreting
chemokines but little iNOS under the inflammatory milieu were capable of attracting immune cells to close proximity without suppressing their proliferation, thereby achieving a potent anti-
tumor effect.